(Q37836904)

24 August 2017

1 reference

title

Current and future directions in mammalian target of rapamycin inhibitors development (English)

1 reference

24 August 2017

1 reference

Angelica Fasolo

1

1 reference

24 August 2017

Cristiana Sessa

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

8 February 2011

1 reference

Expert Opinion on Investigational Drugs

24 August 2017

1 reference

24 August 2017

20

1 reference

24 August 2017

3

1 reference

24 August 2017

381-394

1 reference

Rapamycins: mechanism of action and cellular resistance

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Translational control in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

The role of mTOR in the management of solid tumors: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

mTOR signaling and drug development in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Rapamycin and mTOR kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Rational design of inhibitors that bind to inactive kinase conformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

The pharmacology of mTOR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Targeting mTOR globally in cancer: thinking beyond rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

EORTC-GU group expert opinion on metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Molecular basis of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Oropharyngeal cancer, human papilloma virus, and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

The PTEN-PI3K pathway: of feedbacks and cross-talks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

PI3K and mTOR inhibitors: a new generation of targeted anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Synthesis and function of 3-phosphorylated inositol lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

Targeting TOR dependence in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.541154

10.1517/13543784.2011.541154

21 January 2018

Identifiers

DOI

1 reference

release_s6xtrvh3c5e55j7qbkp6wmnh2i

24 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/s6xtrvh3c5e55j7qbkp6wmnh2i

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference